|Bid||119.12 x 800|
|Ask||119.60 x 1200|
|Day's range||117.74 - 126.19|
|52-week range||67.11 - 126.59|
|Beta (5Y monthly)||1.15|
|PE ratio (TTM)||168.61|
|Earnings date||26 Jul 2023 - 31 Jul 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||140.70|
In a time where recession concerns remain for many investors, and the market is continuing to deal with regular bouts of volatility, it can be easy to lose sight of your long-term investment horizon and get caught up in the day-to-day machinations of the market. If you're looking for two compelling businesses to invest $1,500 in this month, here are two names to consider hitting the buy button on right now. Fiverr (NYSE: FVRR) continues to help customers, from small enterprises to massive brands, connect with freelancers that meet their business needs.
Let's consider three stocks that could: Vertex Pharmaceuticals (NASDAQ: VRTX), DexCom (NASDAQ: DXCM), and Amazon (NASDAQ: AMZN). Vertex Pharmaceuticals is doing great things. One of the drugmakers that was closest to entering this market with competing products recently threw in the towel.
SAN DIEGO, June 01, 2023--DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at William Blair's 43rd Annual Growth Stock Conference on Wednesday, June 7th.
These companies have what it takes to keep growing and enriching investors in the years ahead.
Based on the latest round of 13F filings, a number of prominent billionaire investors piled into three fast-growing stock-split stocks.
Investors continue to be optimistic about DexCom (DXCM), owing to its strong product portfolio.
While some investors may be discouraged by the market volatility that has continued from last year into 2023, the fact remains that truly great businesses are still growing even in an ongoing economic maelstrom. While a full-fledged recession has the ability to hamper growth across a range of businesses and sectors, when you're looking at a multi-year buy-and-hold horizon for any stock you own, even these periods can be a short window against your overall investment period. DexCom (NASDAQ: DXCM) has built a name for itself as a leader in diabetes care, a highly fragmented space with increasing levels of competition.
Some products and services are bigger than any economic, cultural, technological, or societal cycle.
Given the market volatility over the past few years, some investors are questioning whether they should still be putting their hard-earned money into the stock market. Let's take a closer look at two excellent growth stocks to buy right now: Teladoc Health (NYSE: TDOC) and DexCom (NASDAQ: DXCM). Last year was a horror show for Teladoc.
Recession or not, don't expect these businesses to run out of growth opportunities anytime soon.
Dexcom, Rambus, Advanced Micro Devices, Nvidia and Vipshops are part of the Zacks Investment Ideas article.
Andrew Rocco combines fundamentals and technicals to bring you 3 top stocks on the verge of breaking out.
KAGOSHIMA, Japan, May 10, 2023--DexCom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase the accuracy, reliability and ease of use of its Dexcom G6 CGM System and will highlight the latest clinical evidence that continues to demonstrate the effectiveness of Dexcom CGM during the 66th Annual Meeting of the Japan Diabetes Society held May 11-13, 2023 in Kagoshima, Japan.
SAN DIEGO, May 03, 2023--Dexcom Prices Upsized Offering of $1.1 Billion of 0.375% Convertible Senior Notes Due 2028
EDINBURGH, Scotland, May 03, 2023--Dexcom rtCGM is associated with significant improvements over patients’ lifetimes and is likely to be cost-saving to the NHS
SAN DIEGO, May 02, 2023--Dexcom Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes
A poorly received first-quarter earnings report has investors wondering if this stock's best days are behind it.
Thank you, Abby, and welcome to DexCom's first-quarter 2023 earnings call. Please note that there are also slides available related to our first-quarter performance on the DexCom's investor relations website on the events and presentations page.
DexCom's (DXCM) first-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
DexCom (DXCM) delivered earnings and revenue surprises of 13.33% and 3.01%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO, April 27, 2023--Dexcom Reports First Quarter 2023 Financial Results
As a group, growth stocks had a year to forget in 2022. Let's consider why both healthcare stocks could double in the next five years -- and for those keeping score at home, that amounts to a compound annual growth rate of almost 15%. Vertex Pharmaceuticals is a biotech company best known for its lineup of medicines that treat the underlying causes of cystic fibrosis (CF), a rare genetic disease.
BURNABY, British Columbia, April 27, 2023--Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, applauds the progressive expansion of coverage for continuous glucose monitoring systems through the Non-Insured Health Benefits (NIHB) program. Following an announcement made earlier this year, this decision further broadens the coverage criteria, now enabling any client managing diabetes with insulin to access the standard of care.
Medical Device companies' Q1 results are likely to reflect strength in customer demand. Let's see how WST, DXCM and BAX are placed ahead of their earnings releases.
Eli Lilly (NYSE: LLY) and DexCom (NASDAQ: DXCM) have characteristics in common that, in my view, make them monster stocks to buy without hesitation. Both companies also have major tailwinds that should help drive revenue for years. For DexCom, profits will be driven by the trend toward greater numbers of diabetes patients and their need for continuous glucose monitoring devices (CGMs).